142 related articles for article (PubMed ID: 30758504)
1. Extensive Pigment Incontinence Mimicking Persistent Melanoma After Talimogene Laherparepvec Therapy.
Danesh M; Faulkner-Jones B; Desai A; Kim CC
JAMA Dermatol; 2019 Apr; 155(4):496-497. PubMed ID: 30758504
[No Abstract] [Full Text] [Related]
2. Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
Hsu AC; Kokot NC; Eisenberg BL; Thomas JS
Oral Oncol; 2020 Dec; 111():104899. PubMed ID: 32665184
[TBL] [Abstract][Full Text] [Related]
3. Regression of mucosal melanoma following intralesional talimogene laherparepvec (T-VEC) injection in combination with immunotherapy.
Drescher C; Drexler K; Hilber H; Schmidt B; Haferkamp S
J Dtsch Dermatol Ges; 2019 Mar; 17(3):321-323. PubMed ID: 30698924
[No Abstract] [Full Text] [Related]
4. Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Gutzmer R; Harrington KJ; Hoeller C; Lebbé C; Malvehy J; Öhrling K; Downey G; Dummer R
Eur J Dermatol; 2018 Dec; 28(6):736-749. PubMed ID: 30698145
[TBL] [Abstract][Full Text] [Related]
5. Future Directions and Challenges Facing Intralesional Immunotherapy With Talimogene Laherparepvec for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2021 Jan; 47(1):132-133. PubMed ID: 31574028
[No Abstract] [Full Text] [Related]
6. Talimogene laherparepvec pseudolymphomatous reaction mimicking metastatic melanoma.
Henning A; Agnese D; Chung CG
J Cutan Pathol; 2021 Nov; 48(11):1423-1426. PubMed ID: 34189749
[TBL] [Abstract][Full Text] [Related]
7. Talimogene laherparepvec (T-VEC) in advanced melanoma: complete response in a heart and kidney transplant patient. A case report.
Ressler J; Silmbrod R; Stepan A; Tuchmann F; Cicha A; Uyanik-Ünal K; Hoeller C
Br J Dermatol; 2019 Jul; 181(1):186-189. PubMed ID: 30776080
[TBL] [Abstract][Full Text] [Related]
8. Rash after a single injection of T-VEC.
Wagenknecht D; Kohlmann J; Rütten A; Ziemer M
J Dtsch Dermatol Ges; 2019 Jun; 17(6):649-651. PubMed ID: 30920764
[No Abstract] [Full Text] [Related]
9. Talimogene Laherparepvec Use in Kidney Transplant Recipient.
Gupta M; Brennan DC; Alhamad T
Transplantation; 2020 Apr; 104(4):e109-e110. PubMed ID: 31815902
[No Abstract] [Full Text] [Related]
10. Kaposi's varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab.
Miller DM; Trowbridge RM; Desai A; Drews RE
J Immunother Cancer; 2018 Nov; 6(1):122. PubMed ID: 30454071
[TBL] [Abstract][Full Text] [Related]
11. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Andtbacka RHI; Collichio F; Harrington KJ; Middleton MR; Downey G; Ӧhrling K; Kaufman HL
J Immunother Cancer; 2019 Jun; 7(1):145. PubMed ID: 31171039
[TBL] [Abstract][Full Text] [Related]
12. Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Mohr P; Haferkamp S; Pinter A; Weishaupt C; Huber MA; Downey G; Öhrling K; Loquai C; Louie KS
Adv Ther; 2019 Jan; 36(1):101-117. PubMed ID: 30536143
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL
J Clin Oncol; 2018 Jun; 36(17):1658-1667. PubMed ID: 28981385
[TBL] [Abstract][Full Text] [Related]
14. How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma.
Queen D; Samie FH; Zeitouni NC
Dermatol Surg; 2020 Nov; 46(11):1455-1457. PubMed ID: 31403542
[No Abstract] [Full Text] [Related]
15. Ultrasound-guided Intralesional Injection of Talimogene laherparepvec (Imlygic) for Advanced Melanoma: Technical Note on a Preliminary Experience.
Burke LMB; Yu H; Burke K; Gwynn M; Louie RJ; Ollila DW; Rn PL; Collichio F
Cardiovasc Intervent Radiol; 2021 May; 44(5):801-806. PubMed ID: 33447922
[TBL] [Abstract][Full Text] [Related]
16. Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.
MacArthur TA; Fahy AS; Jakub JW
Am Surg; 2021 Jun; 87(6):849-854. PubMed ID: 34060947
[TBL] [Abstract][Full Text] [Related]
17. Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab.
Naqash AR; Stroud G; Collichio FA; Muzaffar M; Sharma N; Walker P
Acta Oncol; 2017 Oct; 56(10):1327-1330. PubMed ID: 28481677
[No Abstract] [Full Text] [Related]
18. The histological spectrum of talimogene laherparepvec (TVEC) injections-Neutrophilic and chronic granulomatous dermatitis.
Lee K; Pouldar D; Shiu J; Elsensohn A; de Feraudy S
J Cutan Pathol; 2019 Feb; 46(2):165-167. PubMed ID: 30414194
[No Abstract] [Full Text] [Related]
19. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience.
Perez MC; Miura JT; Naqvi SMH; Kim Y; Holstein A; Lee D; Sarnaik AA; Zager JS
Ann Surg Oncol; 2018 Dec; 25(13):3960-3965. PubMed ID: 30298318
[TBL] [Abstract][Full Text] [Related]
20. Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition.
Roberts ME; Vines K; Sullivan FG; Phung T; Liles JS; Howard JH
Am Surg; 2024 Jun; 90(6):1809-1812. PubMed ID: 38562109
[No Abstract] [Full Text] [Related]
[Next] [New Search]